Aesica invests £3m in high containment facility

Will enable the firm to manufacture potent drugs from May 2011

UK pharmaceutical manufacturer Aesica is investing £3m in a new high containment facility, significantly extending its capabilities in the formulation and packaging of liquid and solid dosage forms.

Aesica estimates that the facility, housed in a purpose-built facility at its Queenborough, Kent site, will be completed by May 2011 and once operational will manufacture potent drugs typically classed as Safebridge category 3. The facility will also include security measures to enable it to produce Schedule II controlled drugs such as opiates.

Suites for granulation, tabletting and blister packing, plus appropriate HVAC and cleaning facilities will be built in the high containment unit. It will be separate from the rest of the company’s facilities to prevent cross-contamination.

Adam Sims, Aesica’s commercial director, said: ‘Our service offering and capability is the most advanced in the UK and the addition of the new facility will be of huge benefit to our current clients and indeed all pharmaceutical companies who require potent drug product production.’

Aesica supplies contract development and contract manufacturing services for active pharmaceutical ingredients and formulated products to the world’s leading pharmaceutical companies and emerging biotechnology organisations.

Companies